Result: Exceptionally, 13 S mutations presented the higher distributions (p<0.1) in the HCC group: F20S (8.2% vs 1%, p = 0.015), D33G (4.1% vs 0%, p = 0.039), (T47A/E/V/K (18.4% vs 7.1%, p = 0.025), <
Discussion: We found mutations as Y100C/F, P120S/T, R122K, I126T/N/S, S132P, M133T/S/L/I, G145R (the vaccine escape mutant, 2%), Y200F/W and Y206H/F/C as same as that were reported from other studies (Hudu et al.
Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.
Abstract: Here, we compared the effects of recombinant HBsAg antigens, wild-type and mutated at G145R, both included in the new vaccine, on activation of a human high-density culture of peripheral blood mononuclear cells (PBMC) in vitro.
Abstract: In contrast, the G145R mutant alone did not affect CD86 expression, it induced less CD69, and stimulated IL-2 along with lowering levels of TNF-alpha, IL-10, and IFN-gamma.
Abstract: Recently, the multivalent vaccine Bubo -Unigep has been developed to protect against both wild-type HBV and the most significant G145R mutant.
Abstract: The dramatic differences in the immune responses elicited by wild-type HBsAg and the G145R mutant HBsAg suggest distinct adaptive capabilities of the
Establishment of monoclonal antibodies broadly neutralize infection of hepatitis B virus.
Abstract: In addition, the antibodies neutralized the infection of hepatitis D virus possessing a Gly145 mutation to Arg in S protein, which is a well-known escape mutation against HBIG treatment.
Analysis of entire hepatitis B virus genomes reveals reversion of mutations to wild type in natural infection, a 15 year follow-up study.
PMID: 34902556
2022
Infection, genetics and evolution
Abstract: Some sequences from subject CC246 had predicted escape substitutions (T123N, G145R) in the surface protein in 2004, 2013 and 2019 but none of the sequences from 2007 had these changes.
Multiple epitopes of hepatitis B virus surface antigen targeted by human plasma-derived immunoglobulins coincide with clinically observed escape mutations.
Abstract: We then tested in binding assays HBsAg peptides containing clinically relevant mutations previously reported within these sites, such as Y134S, P142S, and G145R, and observed a significant reduction in anti-HBs binding activity to the mutated sites, suggesting a mechanism the virus may use to avoid HBIG-mediated neutralization.
Prevalence, genotype distribution and mutations of hepatitis B virus and the associated risk factors among pregnant women residing in the northern shores of Persian Gulf, Iran.
Discussion: P120T and G145R mutations in the S gene are associated with low responses to HBV vaccination and immunoglobulin therapy as well as failures of diagnostic tests.
Discussion: Nevertheless, P120T and G145R mutations associated with failure of HBsAg detection were not found in this sample.
Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy.
Abstract: Genetic sequencing of HBV showed the mutants of S143T, D144G, and G145R in the S gene region, and the mutant of site 1896 in the pre-Core region coexisted with the wild type (G1896A/G).
Result: Mutation analysis of this patient's HBV showed there were three mutants (S143T, D144G, and G145R) in the S gene region, and the mutant of site 1896 in the pre-Core region coexisted with the wild type (G1896A/G), but no mutation in the pre-S1, pre-S2, and
Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.
Abstract: CONCLUSION: ELISA-based detection of escape mutations S143L, D144E and G145R can be used for routine diagnostics, especially in the risk groups.
Abstract: The G145R mutation was recognized using ELISA kit in almost all cases.
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
Result: G145A/R had an overall prevalence of 1.3% (37/2837) and had the highest prevalence in genotype C at 2.2% (24/1102; p = 0.002), and in Asia at 1.6% (34/2109; p = 0.009); this is the best recognized VEM (Figure 2A).
Result: Branches with VEM G145R were estimated to emerge around the year 1930 (95% HPD 1866-1958).
Result: Other VEMs that had an overall prevalence of >1% were T118A/R/V,
Discussion: The global prevalence of the VEM G145A/R in our data was 1.3%, which is comparable to a previous report across genotypes A-F.
Discussion: Using phylogenetic dating, we estimate that RAMs M204V and L180M, and VEM G145R were already present around the mid 20th century.
Molecular characteristics of HBV infection among blood donors tested HBsAg reactive in a single ELISA test in southern China.
Result: In addition, immune escape mutants containing Q129H, T131I/T, G145R, and E164V were also found in these S sequences.
Result: Several mutations associated with the interference of HBsAg detection, such as mutations in the major hydrophilic region (MHR), including Q129H, T131I, M133L/S/T, F134L, T143M, and G145R, and mutations outside the MHR, including Y100C, L175S, and Y103I, were found in S genes among
HBV mutation literature information.
PMID: 
2022
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT